BIOD-531: Preliminary Phase IIa data

Preliminary data from the single-blind, 4-way crossover, U.S. Phase IIa Study 3-151 in 12 Type I and II diabetics with severe insulin resistance showed that subcutaneous BIOD-531 given

Read the full 288 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE